‘Diabetes + hyperlipidemia’ combination therapy market fueled with 3 new products
The market of diabetes and hyperlipidemia has been fueled.
On the 10th, the Ministry of Food and Drug Safety(MFDS) approved CJ HealthCare’s Atomet SR Tab 10/500mg, 10/750mg, 20/500mg and 20/750mg, Daewoong Pharmaceutical’s Lipimet SR Tab 10/500mg, 10/750mg, 20/500mg and 20/750mg, Jeil’s Limitor ...
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.